ArriVent BioPharma Inc
AVBPHealthcare|Biotechnology|USA
$33.69
+0.02 (+0.06%)
Tangible Book
$7.15
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07185997 Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations | Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer | P3 | Recruiting | 480 | RCT, Open-label | Firmonertinib, EGFR-TKI inhibitor based on investigator's choice |
| NCT05607550 Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) | Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer | P3 | Active | 398 | RCT, Open-label | furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy |
| NCT07010419 A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST） | NSCLC, Adjuvant Treatment | P3 | Recruiting | 338 | RCT, Double-blind | Firmonertinib, Placebo |
| NCT07066657 A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer | P1 | Recruiting | 405 | Open-label | MRG007 |
| NCT05364073 Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations | Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer | P1 | Active | 160 | Open-label | Furmonertinib, Furmonertinib, Furmonertinib, Furmonertinib, Furmonertinib |